Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.68 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CCNH | P51946 | 2/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001914 | 1.00 | GBA1 (0.68) | GBA1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6001919 | 1.00 | GBA1 (0.68) | GBA1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5974321 | 1.00 | GBA1 (0.68) | GBA1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5973809 | 1.00 | GBA1 (0.68) | GBA1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7226927 | 0.86 | GBA1 (0.68) | GBA1SLC18A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19358440 | 0.84 | GBA1 (0.80) | GBA1LTB4RLTB4R2 | |
| SCHEMBL19358438 | 0.84 | GBA1 (0.80) | GBA1LTB4RLTB4R2 | |
| SCHEMBL19358439 | 0.84 | GBA1 (0.80) | GBA1LTB4RLTB4R2 | |
| SCHEMBL5974577 | 0.83 | GBA1 (0.47) | GBA1SLC6A2SLC6A4 | |
| SCHEMBL5974091 | 0.83 | GBA1 (0.47) | GBA1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565453-A4 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL|BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1189886-B1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| CN-1218941-C | Process for preparing ethyl-sulfonylpiperidine derivatives | HOFFMANN LA ROCHE (CH) | 2005-09-14 | — | — | CN | disclosed |
| EP-1565453-A1 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1136475-B1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004048364-A1 | 2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-6605723-B2 | Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst | HOFFMAN-LA ROCHE INC. | 2003-08-12 | — | — | US | disclosed |
| EP-1189886-A1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6310213-B1 | GOOD AFFITITY TO THE NMDA RECEPTOR AND THEY ARE THEREFORE USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| CN-1315319-A | Process for preparing ethyl-sulfonylpiperidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-10-03 | — | — | CN | disclosed |
| EP-1136475-A1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000075109-A1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | GRIN1, GRIN3A, GRIN2B | GBA1 2175/4885SLC18A3 180/4885SLC6A2 378/4885 |
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | GRIN2B, GRIN1, GRIN2A | GBA1 2386/4885SLC18A3 1699/4885SLC6A2 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.